Found 37 dm-pulmonary-allergy-and-critical-care trials
A listing of dm-pulmonary-allergy-and-critical-care medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This phase 2b/3 study will use AV-101 dry powder for oral inhalation in patients with PAH. Procedures include PEs, vital signs, safety labs, right heart caths, echocardiograms, QOL questionnaires, 6MWTs, lung function tests, and PK labs.
The study will investigate the eficacy and safety of belumosudil compared with placebo, administered on top of azithromycin and SOC regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, at least 18 years age and with progressive CLAD despite azithromycin.
The purpose of this study is to provide continued treatment with itacitinib to participants who are currently enrolled in the Parent Study of itacitinib.
The main purpose of this study is to see whether inhaling this combination of drugs in RSP-1502 has an acceptable safety profile and works better compared to inhaling tobramycin alone when treating participants with Cystic Fibrosis and chronic Pseudomonas aeruginosa lung infection. Procedures include spirometry, ECG, sputum collection, and pharmacokinetic …
The objectives of this Phase 1/2 prospective interventional trial are to: 1. Evaluate the safety, tolerability, and immunogenicity of a single dose of 4D-710 delivered via nebulization 2. Identify a recommended phase 2 dose (RP2D) for further evaluation 3. Evaluate 4D-710 target gene transduction/expression in bronchoscopic samples (Dose Exploration) and …
Researchers hope to learn more about BMS 986278. The study treatment will be tested at doses of either 120 mg or 60 mg, compared to placebo. There will be 2 cohorts and up to 1185 subjects participating.
Aim: To conduct a pilot open-label study of semaglutide in lung transplant candidates with obesity. - We will get an estimate of recruitment fraction and retention on study drug. - We will determine preliminary effect estimates of change in weight, percent body fat, skeletal muscle mass, and circulating levels of …
This phase 3 study will evaluate bexotograst in patients with IPF. The study will include a CT, PEs, lung function testing, EKGs, vital signs, questionnaires, and safety labs, as well as PK and PD testing.
This protocol will assess the safety and tolerability of BMS 986278 in patients with PPF. It will involve PEs, safety labs, clinical labs, pulmonary tests, EKGs, HRCTs, vital signs, and 6MWTs.
The Investigation Device Exemption (IDE) study will evaluate the safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
